SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress Acquisition Corp., is based in SIOUX FALLS, S.D.
| Revenue (Most Recent Fiscal Year) | $1.32M |
| Net Income (Most Recent Fiscal Year) | $-34.10M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 6.05 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.79 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -9067.72% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -105.14% |
| Return on Assets (Trailing 12 Months) | -69.24% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.69 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.69 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.15 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.30 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.56 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.68 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.70 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 9.29M |
| Free Float | 6.83M |
| Market Capitalization | $16.82M |
| Average Volume (Last 20 Days) | 0.08M |
| Beta (Past 60 Months) | 0.47 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 26.46% |
| Percentage Held By Institutions (Latest 13F Reports) | 7.82% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |